<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01067716</url>
  </required_header>
  <id_info>
    <org_study_id>STAR-107-AVSS</org_study_id>
    <nct_id>NCT01067716</nct_id>
  </id_info>
  <brief_title>Performance and Acceptability of VSS-R</brief_title>
  <official_title>A Prospective Study to Evaluate the Performance and Acceptability of Advanced Variable Spot Scanning (AVSS) Ablations With the STAR S4 IR® Excimer Laser System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Optics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Optics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The results of this trial will demonstrate that AVSS software performs as intended and is
      acceptable in a clinical setting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      LASIK treatment across the range of myopia with or without astigmatism, hyperopia with or
      without astigmatism, and mixed astigmatism.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of Eyes With Uncorrected Visual Acuity (UCVA) of 20/40 or Better</measure>
    <time_frame>1 Year</time_frame>
  </primary_outcome>
  <other_outcome>
    <measure>Percent Manifest Refraction Spherical Equivalent Within 1.0D</measure>
    <time_frame>1 Year</time_frame>
    <description>Manifest refraction spherical equivalent is the required spectacle (or glass) prescription.</description>
  </other_outcome>
  <other_outcome>
    <measure>Loss of More Than 2 Lines Best Spectacle Corrected Visual Acuity (BSCVA)</measure>
    <time_frame>1 Year</time_frame>
    <description>After surgery, with or without best spectacle prescription the subject is not expected to see worse than before surgery. As a metric for this safety endpoint, losses of 2 lines of vision on a standard eye chart, with best spectacle correction, after surgery compared to pre-operative baseline shall be evaluated. For example 20/20 is typically considered best vision and 2 lines worse than this will be 20/32).</description>
  </other_outcome>
  <other_outcome>
    <measure>Induced Manifest Refractive Astigmatism Greater Than 2.0 D of Absolute Cylinder Power</measure>
    <time_frame>1 Year</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Refractive Error</condition>
  <arm_group>
    <arm_group_label>Refractive Error</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>STAR S4IR LASIK with VSS-R ablation profile</intervention_name>
    <description>LASIK treatment targeted for emmetropia</description>
    <arm_group_label>Refractive Error</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, of any race, and at least 21 years old at the time of the
             pre-operative examination and signing the consent form.

          -  The refractive error, based on manifest refraction at the spectacle plane, of: MRSE up
             to -15.00 D with manifest cylinder between 0.00 and -6.00 D; MRSE up to +7.00 D, with
             manifest cylinder between 0.00 and 6.00 D; or Manifest cylinder (from 1.0 to 6.0 D)
             greater than the magnitude of sphere, and the manifest cylinder and sphere have
             opposite signs.

          -  BSCVA of 20/20 or better.

          -  UCVA of 20/40 or worse.

          -  Manifest refraction sphere within ± 0.75 D of cycloplegic refraction sphere (at the
             same vertex distance).

          -  Anticipated post-operative stromal bed thickness of at least 250 microns, based on
             pre-operative central corneal pachymetry minus the maximum treatment depth to be
             ablated and the intended flap thickness, and confirmed by intra-operative central
             corneal pachymetry.

          -  Anticipated post-operative keratometry value (based on pre-operative manifest
             refraction and keratometry) that is appropriate.

          -  A stable refractive error, based on an exam (or prescription) at least 12 months prior
             to the pre-operative examination and as compared to the pre-operative manifest
             refraction

          -  Subjects who have worn a contact lens in the operative eye must discontinue lens wear
             at least three (3) consecutive weeks prior to the pre-operative examination. If, upon
             review of pre-operative measurements, the Investigator determines that the corneal
             topography is within normal limits, surgery may be scheduled (within 60 days), with no
             contact lens wear permitted prior to the surgery.

          -  Willing and capable of returning for follow-up examinations for the duration of the
             study (6 months).

        Exclusion Criteria:

          -  Women who are pregnant, breast-feeding, or intend to become pregnant over the course
             of the study, as determined by verbal inquiry.

          -  Concurrent use of topical or systemic medications that may impair healing, including
             but not limited to: antimetabolites, isotretinoin (Accutane®) within 6 months of
             treatment, and amiodarone hydrochloride (Cordarone®) within 12 months of treatment.

          -  History of any of the following medical conditions, or any other condition that could
             affect wound healing: collagen vascular disease, autoimmune disease, immunodeficiency
             diseases, ocular herpes zoster or herpes simplex, endocrine disorders (including, but
             not limited to unstable thyroid disorders and diabetes), lupus, and rheumatoid
             arthritis.

          -  Subjects with a cardiac pacemaker or implanted defibrillator.

          -  History of prior intraocular or corneal surgery (including cataract extraction),
             active ophthalmic disease or abnormality (including, but not limited to, symptomatic
             blepharitis, recurrent corneal erosion, dry eye syndrome, neovascularization &gt; 1mm
             from limbus), retinal detachment/repair, clinically significant lens opacity, clinical
             evidence of trauma, corneal opacity within the central 9 mm, at risk for developing
             strabismus, or with evidence of glaucoma or propensity for narrow angle glaucoma.

          -  Evidence of keratoconus, corneal dystrophy or irregularity, or abnormal
             videokeratography.

          -  Known sensitivity or inappropriate responsiveness to any of the medications used in
             the post-operative course.

          -  Subjects with one eye that does not meet all inclusion criteria and does not fall
             within approved indications for treatment using the VISX® STAR S4 IR® Excimer Laser.

          -  Participation in any other clinical study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicholas Tarantino, OD</last_name>
    <role>Study Director</role>
    <affiliation>Abbott Medical Optics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Valley Laser Eye Centre</name>
      <address>
        <city>Abbottsford</city>
        <state>British Columbia</state>
        <zip>V2S 3R1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clearly LASIK</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8X 1X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Image Plus Laser Eye Center</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3C 3J5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Ottawa Eye Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8LB</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yonge-Eglington Laser</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4P 2E5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2010</study_first_submitted>
  <study_first_submitted_qc>February 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2010</study_first_posted>
  <results_first_submitted>March 28, 2013</results_first_submitted>
  <results_first_submitted_qc>March 28, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 22, 2013</results_first_posted>
  <last_update_submitted>October 7, 2013</last_update_submitted>
  <last_update_submitted_qc>October 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 31, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Refractive Errors</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>One or both eyes of 79 subjects (150 eyes) were treated.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Myopia With and Without Astigmatism</title>
          <description>Myopia with and without astigmatism with MRSE up to -15.0D, with cylinder between 0.00 and -6.00 D.</description>
        </group>
        <group group_id="P2">
          <title>Hyperopia With and Without Astigmatism</title>
          <description>Hyperopia with and without astigmatism with MRSE up to +9.00 D, with cylinder between 0.00 and +6.00 D.</description>
        </group>
        <group group_id="P3">
          <title>Mixed Astigmatism</title>
          <description>Mixed Astigmatism when the magnitude of cylinder (from 1.0 to 6.0D) is greater than the magnitude of sphere, and the cylinder and sphere have opposite signs.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="57">110 eyes</participants>
                <participants group_id="P2" count="13">25 eyes</participants>
                <participants group_id="P3" count="9">15 eyes</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="57">110 eyes</participants>
                <participants group_id="P2" count="13">25 eyes</participants>
                <participants group_id="P3" count="9">15 eyes</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Myopia With or Without Astigmatism</title>
          <description>Myopia with and without astigmatism with MRSE up to -15.0D, with cylinder between 0.00 and -6.00 D.</description>
        </group>
        <group group_id="B2">
          <title>Hyperopia With and Without Astigmatism</title>
          <description>Hyperopia with and without astigmatism with MRSE up to +9.00 D, with cylinder between 0.00 and +6.00 D.</description>
        </group>
        <group group_id="B3">
          <title>Mixed Astigmatism</title>
          <description>Mixed Astigmatism when the magnitude of cylinder (from 1.0 to 6.0D) is greater than the magnitude of sphere, and the cylinder and sphere have opposite signs.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="57"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="9"/>
            <count group_id="B4" value="79"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent of Eyes With Uncorrected Visual Acuity (UCVA) of 20/40 or Better</title>
        <time_frame>1 Year</time_frame>
        <population>As a measure of effectiveness of LASIK treatment with VSS, distance visual performance without spectacles, clinically measured as Uncorrected Visual Acuity (UCVA) will be measured under standardized conditions such as 4 meter testing distance, controlled ambient room lighting and standard eye charts.</population>
        <group_list>
          <group group_id="O1">
            <title>Myopia With and Without Astigmatism</title>
            <description>Myopia with and without astigmatism with MRSE up to -15.0D, with cylinder between 0.00 and -6.00 D.</description>
          </group>
          <group group_id="O2">
            <title>Hyperopia With and Without Astigmatism</title>
            <description>Hyperopia with and without astigmatism with MRSE up to +9.00 D, with cylinder between 0.00 and +6.00 D.</description>
          </group>
          <group group_id="O3">
            <title>Mixed Astigmatism</title>
            <description>Mixed Astigmatism when the magnitude of cylinder (from 1.0 to 6.0D) is greater than the magnitude of sphere, and the cylinder and sphere have opposite signs.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Eyes With Uncorrected Visual Acuity (UCVA) of 20/40 or Better</title>
          <population>As a measure of effectiveness of LASIK treatment with VSS, distance visual performance without spectacles, clinically measured as Uncorrected Visual Acuity (UCVA) will be measured under standardized conditions such as 4 meter testing distance, controlled ambient room lighting and standard eye charts.</population>
          <units>percentage of eyes</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.1" lower_limit="95.0" upper_limit="100.0"/>
                    <measurement group_id="O2" value="96.0" lower_limit="79.6" upper_limit="99.9"/>
                    <measurement group_id="O3" value="100.0" lower_limit="81.9" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percent Manifest Refraction Spherical Equivalent Within 1.0D</title>
        <description>Manifest refraction spherical equivalent is the required spectacle (or glass) prescription.</description>
        <time_frame>1 Year</time_frame>
        <population>As a measure of effectiveness of LASIK treatment with VSS, the required spectacle prescription, also called manifest refraction, will be measured under standardized conditions such as 4 meter testing distance, controlled ambient room lighting and standard eye charts.</population>
        <group_list>
          <group group_id="O1">
            <title>Myopia With and Without Astigmatism</title>
            <description>Myopia with and without astigmatism with MRSE up to -15.0D, with cylinder between 0.00 and -6.00 D.</description>
          </group>
          <group group_id="O2">
            <title>Hyperopia With and Without Astigmatism</title>
            <description>Hyperopia with and without astigmatism with MRSE up to +9.00 D, with cylinder between 0.00 and +6.00 D.</description>
          </group>
          <group group_id="O3">
            <title>Mixed Astigmatism</title>
            <description>Mixed Astigmatism when the magnitude of cylinder (from 1.0 to 6.0D) is greater than the magnitude of sphere, and the cylinder and sphere have opposite signs.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Manifest Refraction Spherical Equivalent Within 1.0D</title>
          <description>Manifest refraction spherical equivalent is the required spectacle (or glass) prescription.</description>
          <population>As a measure of effectiveness of LASIK treatment with VSS, the required spectacle prescription, also called manifest refraction, will be measured under standardized conditions such as 4 meter testing distance, controlled ambient room lighting and standard eye charts.</population>
          <units>percentage of eyes</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.4" lower_limit="91.0" upper_limit="99.0"/>
                    <measurement group_id="O2" value="92.0" lower_limit="74.0" upper_limit="99.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="81.9" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Loss of More Than 2 Lines Best Spectacle Corrected Visual Acuity (BSCVA)</title>
        <description>After surgery, with or without best spectacle prescription the subject is not expected to see worse than before surgery. As a metric for this safety endpoint, losses of 2 lines of vision on a standard eye chart, with best spectacle correction, after surgery compared to pre-operative baseline shall be evaluated. For example 20/20 is typically considered best vision and 2 lines worse than this will be 20/32).</description>
        <time_frame>1 Year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Myopia With and Without Astigmatism</title>
            <description>Myopia with and without astigmatism with MRSE up to -15.0D, with cylinder between 0.00 and -6.00 D.</description>
          </group>
          <group group_id="O2">
            <title>Hyperopia With and Without Astigmatism</title>
            <description>Hyperopia with and without astigmatism with MRSE up to +9.00 D, with cylinder between 0.00 and +6.00 D.</description>
          </group>
          <group group_id="O3">
            <title>Mixed Astigmatism</title>
            <description>Mixed Astigmatism when the magnitude of cylinder (from 1.0 to 6.0D) is greater than the magnitude of sphere, and the cylinder and sphere have opposite signs.</description>
          </group>
        </group_list>
        <measure>
          <title>Loss of More Than 2 Lines Best Spectacle Corrected Visual Acuity (BSCVA)</title>
          <description>After surgery, with or without best spectacle prescription the subject is not expected to see worse than before surgery. As a metric for this safety endpoint, losses of 2 lines of vision on a standard eye chart, with best spectacle correction, after surgery compared to pre-operative baseline shall be evaluated. For example 20/20 is typically considered best vision and 2 lines worse than this will be 20/32).</description>
          <units>percentage of eyes</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".9" lower_limit="0.0" upper_limit="5.0"/>
                    <measurement group_id="O2" value="4.0" lower_limit="0.1" upper_limit="20.4"/>
                    <measurement group_id="O3" value="0.0">Confidence intervals were not calculated because 0% of eyes had a loss of more than 2 lines of BSCVA</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Induced Manifest Refractive Astigmatism Greater Than 2.0 D of Absolute Cylinder Power</title>
        <time_frame>1 Year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Myopia With and Without Astigmatism</title>
            <description>Myopia with and without astigmatism with MRSE up to -15.0D, with cylinder between 0.00 and -6.00 D.</description>
          </group>
          <group group_id="O2">
            <title>Hyperopia With and Without Astigmatism</title>
            <description>Hyperopia with and without astigmatism with MRSE up to +9.00 D, with cylinder between 0.00 and +6.00 D.</description>
          </group>
          <group group_id="O3">
            <title>Mixed Astigmatism</title>
            <description>Mixed Astigmatism when the magnitude of cylinder (from 1.0 to 6.0D) is greater than the magnitude of sphere, and the cylinder and sphere have opposite signs.</description>
          </group>
        </group_list>
        <measure>
          <title>Induced Manifest Refractive Astigmatism Greater Than 2.0 D of Absolute Cylinder Power</title>
          <units>percentage of eyes</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0">Confidence intervals were not calculated because 0% of eyes had induced manifest refractive astigmatism greater than 2.0 D of absolute cylinder power.</measurement>
                    <measurement group_id="O2" value="0.0">Confidence intervals were not calculated because 0% of eyes had induced manifest refractive astigmatism greater than 2.0 D of absolute cylinder power.</measurement>
                    <measurement group_id="O3" value="0.0">Confidence intervals were not calculated because 0% of eyes had induced manifest refractive astigmatism greater than 2.0 D of absolute cylinder power.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Myopia With or Without Astigmatism</title>
          <description>Myopia with and without astigmatism with MRSE up to -15.0D, with cylinder between 0.00 and -6.00 D.</description>
        </group>
        <group group_id="E2">
          <title>Hyperopia With and Without Astigmatism</title>
          <description>Hyperopia with and without astigmatism with MRSE up to +9.00 D, with cylinder between 0.00 and +6.00 D.</description>
        </group>
        <group group_id="E3">
          <title>Mixed Astigmatism</title>
          <description>Mixed Astigmatism when the magnitude of cylinder (from 1.0 to 6.0D) is greater than the magnitude of sphere, and the cylinder and sphere have opposite signs.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Decrease in BSCVA of greater than or equal to two lines</sub_title>
                <description>Loss of greater than or equal to two lines of BSCVA is an SAE in the context of this study.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Inadvertent insallation of Tropicamide instead of Tetracaine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Elevated IOP (temporary)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Photic phenomena (i.e., halos, glare, starbursts)</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="57"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Corneal Haze</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Double vision</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Superficial epithelial linear laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Peripheral infiltrates</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other - cold/flu</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Other - hairline ankle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>At least ninety (90) days prior to any proposed submission for publication or presentation of Study Data or other findings related to the Study, Institution will provide Sponsor with a manuscript of such submission(s) for review, comment, and approval. For greater certainty, neither Institution nor Principal Investigator shall have any right to publish any information or results concerning the Study without the express written consent of Sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Amelia Saliba</name_or_title>
      <organization>Abbott Medical Optics</organization>
      <phone>408-273-4158</phone>
      <email>amelia.saliba@amo.abbott.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

